Jane Street
PHAT icon

Jane Street’s Phathom Pharmaceuticals PHAT Stock Holding History

Jane Street’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$980K Buy
88,200
+64,100
+266% +$810K ﹤0.01% 6535
2025
Q4 		$400K Sell
24,100
-28,300
-54% -$404K ﹤0.01% 8194
2025
Q3 		$617K Sell
52,400
-155,800
-75% -$1.61M ﹤0.01% 7396
2025
Q2 		$2M Buy
208,200
+198,000
+1,941% +$1.1M ﹤0.01% 4415
2025
Q1 		$64K Buy
+10,200
New +$61.9K ﹤0.01% 8945
2023
Q4 		– Sell
-10,600
Closed -$110K – 9655
2023
Q3 		$110K Sell
10,600
-18,100
-63% -$248K ﹤0.01% 7914
2023
Q2 		$411K Buy
+28,700
New +$331K ﹤0.01% 6622

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return